EcoDrugPlus

Histone Deacetylase 6

Ensembl ID : ENSMMDG00005018921
Gene Symbol: HDAC6
1 Cross references
181 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSMMDG00005006368
Gene Symbol: HDAC7
1 Cross references
195 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSMMDG00005007685
Gene Symbol: HDAC7
1 Cross references
189 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSMMDG00005011498
Gene Symbol: HDAC8
3 Cross references
205 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 3-Like

Ensembl ID : ENSMMDG00005020726
Gene Symbol: LOC115364728
2 Cross references
164 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSMMDG00005001023
Gene Symbol: HCN4
3 Cross references
212 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSMMDG00005024452
Gene Symbol: HCN4
1 Cross references
221 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSMMDG00005010721
Gene Symbol: HCRTR2
3 Cross references
203 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1-Like

Ensembl ID : ENSMMDG00005015058
Gene Symbol: LOC115373821
3 Cross references
211 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSMMDG00005011131
Gene Symbol: IKBKB
3 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSMMDG00005002079
Gene Symbol: IMPDH2
3 Cross references
200 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSMMDG00005015996
Gene Symbol: LOC115355152
3 Cross references
257 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).